Indian Distribution Deal Easy to Stomach

An agreement that will see Finnish biotechnology company Biohit’s diagnostic portfolio marketed across India has been signed with Onsite Diagnostic Labs India Pvt Ltd (ODL). “Utilising the innovative tests from the Biohit portfolio, based on advanced technology, we are making early stomach health screening more accessible and affordable for Indians everywhere,” said Jagdeep Singh, ODL’s CEO.

Included in the distribution agreement are tests for identifying a range of stomach-related ailments; measurement of active B12 vitamin levels circulating in the blood levels of and Celiac Quick test for identifying celiac disease, which contributes to substantial savings in healthcare costs by reducing the number of unnecessary endoscopies.

Other tests that will be added to the distribution agreement will include Biohit’s Calprotectin test, which differentiates inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS) as well as in monitoring treatment in IBD patients and Colon View-Fit, used in the screening of colorectal cancer.